Developer docs
API playgroundTry for free, no card

Search company profiles

ZetrOZ

Full company profile

uuid0004u2k

Namestring
ZetrOZ
Legal namestring
ZetrOZ Systems, LLC
Websiteurl
zetroz.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

ZetrOZ Systems is a privately-held medical device company headquartered in Trumbull, Connecticut that develops and manufactures wearable ultrasound devices for sustained acoustic medicine (sam®) therapy. The company's core technology, OZ Inside™, delivers low-intensity long-duration ultrasound through FDA-cleared wearable patches to treat soft tissue injuries, chronic musculoskeletal pain, and osteoarthritis without surgery or pharmaceuticals. Its product portfolio includes sam® Sport (introduced 2013), sam® 2.0 (2019), sam® X1 (2022), and the newly launched sam® 3.0 (June 2026), supported by advanced 3M hypoallergenic coupling patches.

The company generates revenue primarily through prescription-based hardware sales in the US (distributed via physicians and physical therapists) and direct-to-consumer e-commerce platforms (samrecover.com, samsport.com) in international markets including Canada, the EU, UAE, Malaysia, and Singapore. Its customer base spans professional sports organizations (MLB, NBA, NFL), Olympic and collegiate athletes, US military veterans (under a VA contract), geriatric arthritis patients, orthopaedic surgeons, and frontline workers. The company operates four cGMP and ISO 13485 certified US manufacturing facilities and holds 46-48 global patents.

ZetrOZ is led by founder George K. Lewis, PhD (President & CEO), with JoAnne Guarino as COO, Sabrina Lewis as Director of Regulatory Affairs, and Robert Butler as Controller. The company has received substantial non-dilutive funding from NIH, DOD, NASA, NSF, and Connecticut state government, and has raised venture capital from Connecticut Innovations, Maine Angels, Horizon Technology Finance, and Fort Point Angels. Clinical validation includes 42+ peer-reviewed publications and 20+ clinical studies supporting outcomes such as over 50% faster soft tissue healing, up to 52% pain reduction in osteoarthritis, and over $27,000 in medical cost savings per patient when treatment is introduced early.

Short descriptiontext

ZetrOZ Systems is a privately-held US medical device company that develops and manufactures FDA-cleared wearable ultrasound devices (sam®) for non-invasive treatment of soft tissue injuries, chronic musculoskeletal pain, and osteoarthritis, serving athletes, military veterans, geriatric patients, and healthcare providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTrumbull, United States
HQ citystring
Trumbull
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable ultrasound devices, sustained acoustic medicine, soft tissue healing, chronic pain management, FDA-cleared medical devices
Industry1 code
PRIMARYHLAHABAD
Ultrasound & Echography Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable Therapeutic Ultrasound Medical Devices
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model1 record
1Wearable Ultrasound Device Sales
TypeHardware Sales
Description

Sale of sam® product line devices (sam Sport, sam 2.0, sam X1, sam 3.0) as prescription medical devices for at-home use. Revenue from direct hardware sales through company e-commerce platforms and potentially through healthcare provider prescriptions.

zetroz.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1sam X1 - Prescription-only home use device
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Available by prescription in the US only

zetroz.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1sam®
Description

Sustained Acoustic Medicine product line for wearable ultrasound therapy devices for treating soft-tissue injuries and chronic musculoskeletal conditions

zetroz.com
+7 more records
Core offering1 text field

ZetrOZ Systems develops, manufactures, and sells FDA-cleared wearable ultrasound medical devices under the sam® (Sustained Acoustic Medicine) brand that deliver non-invasive, multi-hour continuous low-intensity ultrasound therapy to accelerate soft-tissue healing and relieve chronic musculoskeletal pain. The company's flagship offerings — sam Sport, sam 2.0, sam X1, and sam 3.0 — are sold through prescription channels, direct e-commerce, and enterprise contracts to professional sports teams and government healthcare programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 50% faster healing of soft tissue injuries compared to standard of care
+4 more records
Product overview1 text field

ZetrOZ Systems offers a portfolio of wearable sustained acoustic medicine (sam) devices for non-invasive treatment of soft-tissue injuries and musculoskeletal conditions. The product line includes: sam Sport (first generation, introduced 2013), sam 2.0 (second generation with improved performance), sam X1 (wireless prescription model), and sam 3.0 (latest generation with extended battery life and dual treatment zones). The devices deliver continuous low-intensity ultrasound therapy through proprietary OZ Inside technology, with supporting sam Advanced Coupling Patches for daily use. All devices are FDA-cleared for daily home use and are supported by clinical research including 42 peer-reviewed publications.

Product and service4 records
1sam 3.0
CategoryWearable Therapeutic Ultrasound Device
Description

Latest generation FDA-cleared wearable ultrasound device delivering sustained acoustic medicine for treating soft-tissue injuries, offering up to 8 hours of continuous battery life, 4-amp fast charging via medical-grade USB-C, improved temperature regulation, and dual independently operated treatment zones for athletes, military personnel, frontline workers, and geriatric patients.

2sam 2.0
CategoryWearable Therapeutic Ultrasound Device
Description

Advanced wearable sustained acoustic medicine device FDA-cleared as the only long-duration ultrasound device cleared for daily home use, featuring up to 4x faster rapid charging, improved ergonomics, military-medical-grade housing, data capture and treatment history monitoring, and 3M hypoallergenic patches with patented gel-capture seals.

3sam Sport
CategoryWearable Therapeutic Ultrasound Device
Description

First FDA-cleared wearable device for multi-hour continuous ultrasound therapy introduced in 2013, delivering ultrasonic waves that penetrate 5 cm into tissue to increase circulation, oxygen and nutrient delivery, and remove waste products from musculoskeletal injury sites for professional and collegiate athletes.

4sam X1
CategoryWearable Therapeutic Ultrasound Device
Description

Wireless ultrasound device for at-home use, the first innovative wireless FDA-cleared device for this application, featuring hypoallergenic 3M patches, smart treatment monitoring, key-lock feature, and gel-capture patches, and available by prescription in the U.S.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeGTM or Marketing Partner
Description

Premier sponsor of Arthritis Foundation's 2026 Pathways Conference; received Ease of Use Certification for sam 2.0; deepening partnership to educate patients on drug-free treatment options for knee osteoarthritis; member of OA Action Alliance coalition led by Arthritis Foundation and CDC

Strategic tierCoreTypeGTM or Marketing Partner
Description

Showcased sam sustained acoustic medicine technology at AAOS annual meeting in New Orleans (March 3-5) as part of efforts to expand adoption among orthopaedic surgeons across the United States

3Professional Baseball Athletic Trainers Society (PBATS)
Strategic tierCoreTypeGTM or Marketing Partner
Description

Partnership to educate professional baseball teams on sam technology; company attends MLB spring training camps to present technology for athlete recovery

pharmiweb.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major Sports Medicine Partnership for promoting sustained acoustic medicine technology in athletic recovery programs

5National Basketball Trainers Association (NBATA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major Sports Medicine Partnership supporting athletic trainers and player recovery

zetroz.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research funding from NIH and National Institute of Minority Health and Health Disparities for arthritis treatment development; NIH Phase II SBIR grant for next generation sam technology

Strategic tierCoreTypeStrategic or Co-development Partner
Description

USAMMA Phase II contract to accelerate healing of soft tissue injuries; research shows over 50% improvement vs standard of care

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NSBRI Award and SBIR/STTR Grant for space technology development; research on wearable ultrasound for astronauts and space applications

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Thomas Best serves as team physician and research director; NIH-funded laboratory for muscle inflammation and repair research

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. David Draper leads research and clinical education; 114 publications in scholarly journals; co-author of leading therapeutic modalities textbook

11American Sports Medicine Institute (Dr. Kevin Wilk)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Rehabilitation consultant for Tampa Bay Rays; 155+ journal articles on sports injury rehabilitation

zetroz.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Designated as Approved Vendor for senior healthcare audience; reaching geriatric patient demographic

Strategic tierMinorTypeGTM or Marketing Partner
Description

Participated in Global Knee Summit in Dubai (January 2026) delivering educational talks on sam technology

14National Orthopedic Foundation
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for 2022 supporting research and development of innovative treatments in mechanobiology

zetroz.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Zynex markets non-opioid pain management devices (TENS, NMES, monitoring) prescribed by physicians and PTs. Comparable to ZetrOZ in the prescription-based, non-opioid pain management category and similar physician-channel GTM motion, although Zynex uses electrical rather than ultrasound energy.

2BTL Group
TypeDirect peer
Description

BTL develops non-invasive therapeutic devices for musculoskeletal pain and rehabilitation, including EMTT (extracorporeal magnetotransduction therapy) and shockwave systems. Comparable to ZetrOZ as a non-pharmaceutical, device-based pain management company serving orthopaedic and physical therapy channels.

TypeBroad incumbent
Description

Stryker is a major orthopaedic and medical-surgical company whose Sports Medicine and Orthopaedics divisions overlap with ZetrOZ's athlete and orthopaedic surgeon customer base. Comparable as a broad incumbent with adjacent sports-medicine devices and similar end customers, though Stryker's portfolio is much wider and primarily surgical/implantable.

TypeBroad incumbent
Description

Medtronic's Pain Therapies franchise (intrathecal drug delivery, spinal cord stimulation) is one of the largest non-opioid chronic pain platforms. Comparable to ZetrOZ in addressing chronic musculoskeletal pain as an alternative to opioid/surgical intervention, though Medtronic serves it via implanted devices in a much broader portfolio.

TypeBroad incumbent
Description

Abbott's Neuromodulation business (Proclaim DRG, dorsal root ganglion stimulation) targets chronic pain and is a broader incumbent in non-opioid pain management. Comparable to ZetrOZ as an alternative-to-medication chronic pain therapy, though Abbott operates at far greater scale and via implantable rather than wearable delivery.

TypeEmerging player
Description

Soliton is developing Rapid Acoustic Pulse (RAP) technology for therapeutic and aesthetic indications. Comparable to ZetrOZ as an emerging player using acoustic energy in a medical device format, though Soliton has historically focused on aesthetic tattoo removal rather than musculoskeletal pain.

TypeBroad incumbent
Description

Enovis (formerly DJO) is a large orthopaedic and recovery sciences company offering bracing, pain management, and rehabilitation products used by surgeons, PTs, and athletic trainers. Comparable to ZetrOZ in serving orthopaedic surgeons and physical therapy channels with non-invasive musculoskeletal therapies, though at much broader scale.

TypeDirect peer
Description

Misonix (now part of Bioventus) manufactures therapeutic and surgical ultrasound systems used in wound healing and tissue repair. Most directly comparable to ZetrOZ as another ultrasound-based therapeutic medical device company targeting soft-tissue recovery.

TypeDirect peer
Description

BioElectronics makes wearable, drug-free medical devices (e.g., ActiPatch) for chronic and post-surgical pain relief. Closely comparable to ZetrOZ in delivery mechanism (wearable OTC/prescription device), target indications (soft-tissue pain), and consumer/healthcare dual channel.

10Ivivi Health Sciences (now Endonovo Therapeutics)
TypeEmerging player
Description

Endonovo (formerly Ivivi) markets pulsed electromagnetic field (PEMF) therapy devices for pain and soft-tissue conditions. Comparable to ZetrOZ as a smaller non-invasive, non-pharmaceutical medical device company competing in the same chronic pain and recovery category through different energy modality.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZetrOZ

Wearable Therapeutic Ultrasound Medical Deviceszetroz.com

ZetrOZ Systems is a privately-held US medical device company that develops and manufactures FDA-cleared wearable ultrasound devices (sam®) for non-invasive treatment of soft tissue injuries, chronic musculoskeletal pain, and osteoarthritis, serving athletes, military veterans, geriatric patients, and healthcare providers.

What ZetrOZ does

ZetrOZ Systems is a privately-held medical device company headquartered in Trumbull, Connecticut that develops and manufactures wearable ultrasound devices for sustained acoustic medicine (sam®) therapy. The company's core technology, OZ Inside™, delivers low-intensity long-duration ultrasound through FDA-cleared wearable patches to treat soft tissue injuries, chronic musculoskeletal pain, and osteoarthritis without surgery or pharmaceuticals. Its product portfolio includes sam® Sport (introduced 2013), sam® 2.0 (2019), sam® X1 (2022), and the newly launched sam® 3.0 (June 2026), supported by advanced 3M hypoallergenic coupling patches.

The company generates revenue primarily through prescription-based hardware sales in the US (distributed via physicians and physical therapists) and direct-to-consumer e-commerce platforms (samrecover.com, samsport.com) in international markets including Canada, the EU, UAE, Malaysia, and Singapore. Its customer base spans professional sports organizations (MLB, NBA, NFL), Olympic and collegiate athletes, US military veterans (under a VA contract), geriatric arthritis patients, orthopaedic surgeons, and frontline workers. The company operates four cGMP and ISO 13485 certified US manufacturing facilities and holds 46-48 global patents.

ZetrOZ is led by founder George K. Lewis, PhD (President & CEO), with JoAnne Guarino as COO, Sabrina Lewis as Director of Regulatory Affairs, and Robert Butler as Controller. The company has received substantial non-dilutive funding from NIH, DOD, NASA, NSF, and Connecticut state government, and has raised venture capital from Connecticut Innovations, Maine Angels, Horizon Technology Finance, and Fort Point Angels. Clinical validation includes 42+ peer-reviewed publications and 20+ clinical studies supporting outcomes such as over 50% faster soft tissue healing, up to 52% pain reduction in osteoarthritis, and over $27,000 in medical cost savings per patient when treatment is introduced early.

ZetrOZ firmographics

Firmographics
Name
ZetrOZ
Legal name
ZetrOZ Systems, LLC
Website
https://zetroz.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
ZetrOZ Systems is a privately-held US medical device company that develops and manufactures FDA-cleared wearable ultrasound devices (sam®) for non-invasive treatment of soft tissue injuries, chronic musculoskeletal pain, and osteoarthritis, serving athletes, military veterans, geriatric patients, and healthcare providers.
Ownership category
akta.pro rank

ZetrOZ industry classification

Industry
Product category
Wearable Therapeutic Ultrasound Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHABAD
Ultrasound & Echography Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Wearable ultrasound devices
  • Sustained acoustic medicine
  • Soft tissue healing
  • Chronic pain management
  • FDA-cleared medical devices

Where ZetrOZ is headquartered

Location

Headquarters

HQ city
Trumbull
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ZetrOZ business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Wearable Ultrasound Device Sales: Sale of sam® product line devices (sam Sport, sam 2.0, sam X1, sam 3.0) as prescription medical devices for at-home use. Revenue from direct hardware sales through company e-commerce platforms and potentially through healthcare provider prescriptions.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-gosam X1 - Prescription-only home use device

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

ZetrOZ product offering

Product offering

Core offering

ZetrOZ Systems develops, manufactures, and sells FDA-cleared wearable ultrasound medical devices under the sam® (Sustained Acoustic Medicine) brand that deliver non-invasive, multi-hour continuous low-intensity ultrasound therapy to accelerate soft-tissue healing and relieve chronic musculoskeletal pain. The company's flagship offerings — sam Sport, sam 2.0, sam X1, and sam 3.0 — are sold through prescription channels, direct e-commerce, and enterprise contracts to professional sports teams and government healthcare programs.

Product overview

ZetrOZ Systems offers a portfolio of wearable sustained acoustic medicine (sam) devices for non-invasive treatment of soft-tissue injuries and musculoskeletal conditions. The product line includes: sam Sport (first generation, introduced 2013), sam 2.0 (second generation with improved performance), sam X1 (wireless prescription model), and sam 3.0 (latest generation with extended battery life and dual treatment zones). The devices deliver continuous low-intensity ultrasound therapy through proprietary OZ Inside technology, with supporting sam Advanced Coupling Patches for daily use. All devices are FDA-cleared for daily home use and are supported by clinical research including 42 peer-reviewed publications.

Differentiator

Problem solved

Functional benefit

Brands

  • sam®: Sustained Acoustic Medicine product line for wearable ultrasound therapy devices for treating soft-tissue injuries and chronic musculoskeletal conditions
  • sam® Sport
  • sam® 2.0
  • sam® X1
  • sam® 3.0
  • OZ Inside™
  • samrecover.com
  • samsport.com

Products and services

  • sam 3.0 Latest generation FDA-cleared wearable ultrasound device delivering sustained acoustic medicine for treating soft-tissue injuries, offering up to 8 hours of continuous battery life, 4-amp fast charging via medical-grade USB-C, improved temperature regulation, and dual independently operated treatment zones for athletes, military personnel, frontline workers, and geriatric patients.
  • sam 2.0 Advanced wearable sustained acoustic medicine device FDA-cleared as the only long-duration ultrasound device cleared for daily home use, featuring up to 4x faster rapid charging, improved ergonomics, military-medical-grade housing, data capture and treatment history monitoring, and 3M hypoallergenic patches with patented gel-capture seals.
  • sam Sport First FDA-cleared wearable device for multi-hour continuous ultrasound therapy introduced in 2013, delivering ultrasonic waves that penetrate 5 cm into tissue to increase circulation, oxygen and nutrient delivery, and remove waste products from musculoskeletal injury sites for professional and collegiate athletes.
  • sam X1 Wireless ultrasound device for at-home use, the first innovative wireless FDA-cleared device for this application, featuring hypoallergenic 3M patches, smart treatment monitoring, key-lock feature, and gel-capture patches, and available by prescription in the U.S.

Quantifiable outcome

  • Over 50% faster healing of soft tissue injuries compared to standard of care
  • +4 more outcomes

Companies that use ZetrOZ

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

ZetrOZ technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ZetrOZ partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • Arthritis FoundationcoreGTM or Marketing PartnerPremier sponsor of Arthritis Foundation's 2026 Pathways Conference; received Ease of Use Certification for sam 2.0; deepening partnership to educate patients on drug-free treatment options for knee osteoarthritis; member of OA Action Alliance coalition led by Arthritis Foundation and CDC
  • American Academy of Orthopaedic Surgeons (AAOS)coreGTM or Marketing PartnerShowcased sam sustained acoustic medicine technology at AAOS annual meeting in New Orleans (March 3-5) as part of efforts to expand adoption among orthopaedic surgeons across the United States
  • Professional Baseball Athletic Trainers Society (PBATS)coreGTM or Marketing PartnerPartnership to educate professional baseball teams on sam technology; company attends MLB spring training camps to present technology for athlete recovery
  • USA Field HockeycoreStrategic or Co-development PartnerMajor Sports Medicine Partnership for promoting sustained acoustic medicine technology in athletic recovery programs
  • National Basketball Trainers Association (NBATA)coreStrategic or Co-development PartnerMajor Sports Medicine Partnership supporting athletic trainers and player recovery
  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerResearch funding from NIH and National Institute of Minority Health and Health Disparities for arthritis treatment development; NIH Phase II SBIR grant for next generation sam technology
  • U.S. Department of Defense (DOD)coreStrategic or Co-development PartnerUSAMMA Phase II contract to accelerate healing of soft tissue injuries; research shows over 50% improvement vs standard of care
  • NASA / National Space Biomedical Research InstitutecoreStrategic or Co-development PartnerNSBRI Award and SBIR/STTR Grant for space technology development; research on wearable ultrasound for astronauts and space applications
  • University of Miami Sports Medicine InstitutecoreStrategic or Co-development PartnerDr. Thomas Best serves as team physician and research director; NIH-funded laboratory for muscle inflammation and repair research
  • Brigham Young University - Dept of Exercise SciencesminorStrategic or Co-development PartnerDr. David Draper leads research and clinical education; 114 publications in scholarly journals; co-author of leading therapeutic modalities textbook
  • American Sports Medicine Institute (Dr. Kevin Wilk)minorStrategic or Co-development PartnerRehabilitation consultant for Tampa Bay Rays; 155+ journal articles on sports injury rehabilitation
  • OurSeniors.net MagazineminorGTM or Marketing PartnerDesignated as Approved Vendor for senior healthcare audience; reaching geriatric patient demographic
  • Global Knee SummitminorGTM or Marketing PartnerParticipated in Global Knee Summit in Dubai (January 2026) delivering educational talks on sam technology
  • National Orthopedic FoundationminorStrategic or Co-development PartnerPartnership for 2022 supporting research and development of innovative treatments in mechanobiology

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

ZetrOZ competitors and assessment

Company assessment

Direct peers

  • Zynex Medical: Zynex markets non-opioid pain management devices (TENS, NMES, monitoring) prescribed by physicians and PTs. Comparable to ZetrOZ in the prescription-based, non-opioid pain management category and similar physician-channel GTM motion, although Zynex uses electrical rather than ultrasound energy.
  • BTL Group: BTL develops non-invasive therapeutic devices for musculoskeletal pain and rehabilitation, including EMTT (extracorporeal magnetotransduction therapy) and shockwave systems. Comparable to ZetrOZ as a non-pharmaceutical, device-based pain management company serving orthopaedic and physical therapy channels.
  • Misonix (Bioventus): Misonix (now part of Bioventus) manufactures therapeutic and surgical ultrasound systems used in wound healing and tissue repair. Most directly comparable to ZetrOZ as another ultrasound-based therapeutic medical device company targeting soft-tissue recovery.
  • BioElectronics Corporation: BioElectronics makes wearable, drug-free medical devices (e.g., ActiPatch) for chronic and post-surgical pain relief. Closely comparable to ZetrOZ in delivery mechanism (wearable OTC/prescription device), target indications (soft-tissue pain), and consumer/healthcare dual channel.

Broad incumbents

  • Stryker Corporation: Stryker is a major orthopaedic and medical-surgical company whose Sports Medicine and Orthopaedics divisions overlap with ZetrOZ's athlete and orthopaedic surgeon customer base. Comparable as a broad incumbent with adjacent sports-medicine devices and similar end customers, though Stryker's portfolio is much wider and primarily surgical/implantable.
  • Medtronic (Pain Therapies): Medtronic's Pain Therapies franchise (intrathecal drug delivery, spinal cord stimulation) is one of the largest non-opioid chronic pain platforms. Comparable to ZetrOZ in addressing chronic musculoskeletal pain as an alternative to opioid/surgical intervention, though Medtronic serves it via implanted devices in a much broader portfolio.
  • Abbott (Neuromodulation): Abbott's Neuromodulation business (Proclaim DRG, dorsal root ganglion stimulation) targets chronic pain and is a broader incumbent in non-opioid pain management. Comparable to ZetrOZ as an alternative-to-medication chronic pain therapy, though Abbott operates at far greater scale and via implantable rather than wearable delivery.
  • DJO / Enovis: Enovis (formerly DJO) is a large orthopaedic and recovery sciences company offering bracing, pain management, and rehabilitation products used by surgeons, PTs, and athletic trainers. Comparable to ZetrOZ in serving orthopaedic surgeons and physical therapy channels with non-invasive musculoskeletal therapies, though at much broader scale.

Emerging players

  • Soliton: Soliton is developing Rapid Acoustic Pulse (RAP) technology for therapeutic and aesthetic indications. Comparable to ZetrOZ as an emerging player using acoustic energy in a medical device format, though Soliton has historically focused on aesthetic tattoo removal rather than musculoskeletal pain.
  • Ivivi Health Sciences (now Endonovo Therapeutics): Endonovo (formerly Ivivi) markets pulsed electromagnetic field (PEMF) therapy devices for pain and soft-tissue conditions. Comparable to ZetrOZ as a smaller non-invasive, non-pharmaceutical medical device company competing in the same chronic pain and recovery category through different energy modality.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ZetrOZ social profiles

Digital presence

ZetrOZ compliance and trust

Trust signal

Compliance4 records

ZetrOZ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZetrOZ leadership team

Management profile

Number of profiles

Profiles4 records

ZetrOZ funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZetrOZ M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZetrOZ

What does ZetrOZ do?

ZetrOZ Systems develops, manufactures, and sells FDA-cleared wearable ultrasound medical devices under the sam® (Sustained Acoustic Medicine) brand that deliver non-invasive, multi-hour continuous low-intensity ultrasound therapy to accelerate soft-tissue healing and relieve chronic musculoskeletal pain. The company's flagship offerings — sam Sport, sam 2.0, sam X1, and sam 3.0 — are sold through prescription channels, direct e-commerce, and enterprise contracts to professional sports teams and government healthcare programs.

Is ZetrOZ a public or private company?

ZetrOZ is a private company. It is classified as venture growth investor backed and is currently operating.

When was ZetrOZ founded?

ZetrOZ was founded in 2006. It employs 11 to 50 people.

Where is ZetrOZ based?

ZetrOZ is headquartered in Trumbull, United States, in the North America region.

How does ZetrOZ make money?

One revenue line is on record: wearable Ultrasound Device Sales.

Who are ZetrOZ's main competitors?

Direct peers on record are Zynex Medical, BTL Group, Misonix (Bioventus) and BioElectronics Corporation. Broad incumbents are Stryker Corporation, Medtronic (Pain Therapies), Abbott (Neuromodulation) and DJO / Enovis. Emerging players are Soliton and Ivivi Health Sciences (now Endonovo Therapeutics).

Does ZetrOZ have an API?

No public API is recorded for ZetrOZ.

What industry is ZetrOZ in?

ZetrOZ's product category is Wearable Therapeutic Ultrasound Medical Devices. Its primary akta.pro industry code is HLAHABAD, Ultrasound & Echography Systems. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpacesam(R) 3.0 Now Covered Under Workers’ Compensation and Secondary Insurance for Professional and Collegiate AthletesZetrOZ Systems announced that its wearable ultrasound device sam 3.0 is now covered under workers' compensation and secondary insurance for professional and collegiate athletes. The FDA-cleared device, built on sustained acoustic medicine technology, aims to help athletes recover from soft-tissue injuries without surgery or opioids. Coverage removes a common barrier to access for athletic programs.The future of tradingsam(R) 3.0 Now Covered Under Workers' Compensation and Secondary Insurance for Professional and Collegiate AthletesZetrOZ Systems announced that its sam 3.0 wearable ultrasound device is now covered under workers' compensation and secondary insurance for professional and collegiate athletes. The FDA-cleared device, built on sustained acoustic medicine technology, aims to help athletes recover from soft-tissue injuries without surgery or opioids. Coverage is intended to remove out-of-pocket barriers for athletic programs.FinancialContent Business Pagesam(R) 3.0 Now Covered Under Workers' Compensation and Secondary Insurance for Professional and Collegiate AthletesZetrOZ Systems announced that its sam 3.0 wearable ultrasound device is now covered under workers' compensation and secondary insurance for professional and collegiate athletes. The FDA-cleared device, built on sustained acoustic medicine technology, aims to help athletes recover from soft-tissue injuries without surgery or opioids. Coverage is intended to make the device accessible without out-of-pocket payment.FinancialContent Business PageNFL Players Face a 41% Injury Risk Each Season. sam(R) Offers a Non-Invasive Recovery Option Trusted by Pro Football's Medical StaffZetrOZ Systems is promoting its FDA-cleared sam® wearable ultrasound device to NFL athletic trainers, citing a 41% lower-extremity injury risk per season. The device is FDA-cleared for soft-tissue injuries and knee osteoarthritis, with over 40 published studies supporting its effectiveness.FinancialContent Business PageAs WCI 2026 Turns to Non-Surgical, Opioid-Sparing Care for Injured Workers, ZetrOZ Brings the Outcomes Data to Booth #701ZetrOZ Systems is exhibiting its sam® wearable ultrasound device and sam® Recover at Booth #701 at the 80th Annual Workers' Compensation Educational Conference in Orlando, Aug. 23-26, presenting peer-reviewed research on non-opioid, non-surgical recovery. The company cites over 30 clinical studies, more than 300,000 patients treated, and roughly two-thirds lower case costs, from nearly $40,000 to about $12,000.FinancialContent Business PageZetrOZ Systems Delivers the Future of Sports Medicine Soft Tissue Injury Treatment with National Launch of sam 3.0 at NATA in Philadelphia USA to Celebrate 250 Years of American InnovationZetrOZ Systems unveiled its new sam® 3.0 wearable ultrasound device at the National Athletic Trainers Association annual meeting in Philadelphia on June 29-July 2, marking the national launch of the FDA-cleared technology for soft-tissue injury treatment. The device, validated in 40 clinical studies, introduces enhanced usability, extended battery performance, automatic treatment adjustments, and improved patient experience compared to its predecessor. The launch featured endorsements from physicians, professional athletes, military veterans, and athletic trainers who praised the technology's advancements.MorningstarZetrOZ Systems Delivers the Future of Sports Medicine Soft Tissue Injury Treatment with National Launch of sam 3.0 at NATA in Philadelphia USA to Celebrate 250 Years of American InnovationZetrOZ Systems launched sam 3.0 at the NATA meeting in Philadelphia, presenting the wearable ultrasound device for soft-tissue injury recovery. The device, validated in 40 studies, features enhanced usability, longer battery life, and automated treatment adjustments. The company also reaffirmed its commitment to the NATA Research & Education Foundation.NewswireZetrOZ Systems Delivers the Future of Sports Medicine Soft Tissue Injury Treatment with National Launch of sam 3.0 at NATA in Philadelphia USA to Celebrate 250 Years of American InnovationZetrOZ Systems announced the national launch of its sam 3.0 device at the National Athletic Trainers Association meeting in Philadelphia, USA, positioning it as a clinically validated and FDA-cleared treatment for soft tissue injuries in athletes and active individuals. The device has received endorsements from physicians, professional athletes, and military veterans, underscoring its market credibility. The launch coincides with the commemoration of 250 years of American innovation.FinancialContent Business PageZetrOZ Systems Introduces sam 3.0 Multi-hour Continuous Ultrasound Wearable Technology, The Next Evolution in RecoveryZetrOZ Systems announced the launch of its sam® 3.0 wearable ultrasound device, the latest evolution of its FDA-cleared sustained acoustic medicine technology for treating soft-tissue injuries. The new device offers up to 8 hours of continuous battery life, 4-amp fast charging via medical-grade USB-C, improved temperature regulation, and dual independently operated treatment zones. The company, which has developed the technology across 48 U.S. and global patents with research funding from the National Institutes of Health, Department of Defense, and NASA, targets athletes, military personnel, frontline workers, and geriatric patients seeking drug-free recovery options.BioSpaceZetrOZ Systems and National Foundations Partner to Expand Research and Access to New, Evidence-Based HealthcareZetrOZ Systems expanded partnerships with the Osteoarthritis Action Alliance, Orthopaedic Foundation, and NATA Research & Education Foundation to promote its sam wearable ultrasound device for soft-tissue injuries. The FDA-cleared device, backed by 48 patents, has been used in millions of treatments and is supported by over 40 peer-reviewed studies.